Evidence map›Paper›PMID 36180576›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2022

Clinicopathologic and molecular spectrum of testicular sex cord-stromal tumors not amenable to specific histopathologic subclassification.

Stephanie E Siegmund, Lynette M Sholl, Harrison K Tsai, Yiying Yang, Varshini Vasudevaraja, Ivy Tran, Matija Snuderl, Christopher D M Fletcher, Kristine M Cornejo, Muhammad T Idrees and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 9 institutions in 2 countries.

Stephanie E SiegmundDepartment of Pathology, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA.
Lynette M ShollDepartment of Pathology, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-9532-9735
Harrison K TsaiDepartment of Pathology, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-1134-9331
Yiying YangDepartment of Pathology, NYU Langone Health, New York, NY, USA.
Varshini VasudevarajaDepartment of Pathology, NYU Langone Health, New York, NY, USA.
Ivy TranDepartment of Pathology, NYU Langone Health, New York, NY, USA.
Matija SnuderlDepartment of Pathology, NYU Langone Health, New York, NY, USA.
Christopher D M FletcherDepartment of Pathology, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA.
Kristine M CornejoDepartment of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-9490-8583
Muhammad T IdreesDepartment of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0001-6611-6389
Khaleel I Al-ObaidyDepartment of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0001-9890-8751
Katrina CollinsDepartment of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA.
Jennifer B GordetskyDepartment of Pathology, Vanderbilt University Medical Center/Vanderbilt University, Nashville, TN, USA.ORCID 0000-0002-0745-2160
Sara E WobkerDepartment of Pathology, University of North Carolina Medical Center/University of North Carolina, Chapel Hill, NC, USA.
Michelle S HirschDepartment of Pathology, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-8767-8564
Kiril TrpkovDepartment of Pathology, Rockyview General Hospital/University of Calgary, Calgary, AB, Canada.ORCID 0000-0003-3142-8846
Asli YilmazDepartment of Pathology, Rockyview General Hospital/University of Calgary, Calgary, AB, Canada.
William J AndersonDepartment of Pathology, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA.
Gabriela Quiroga-GarzaDepartment of Pathology, University of Pittsburgh Medical Center Shadyside, Pittsburgh, PA, USA.
Cristina Magi-GalluzziDepartment of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama, UK.ORCID 0000-0003-1219-3797
Sofia Canete-PortilloDepartment of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama, UK.
Andres M AcostaDepartment of Pathology, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA. aacosta4@bwh.harvard.edu.
Brigham and Women's Hospital · USNYU Langone Health · USIndiana University School of MedicineUniversity of Alabama at Birmingham · USUniversity of Calgary · CAHarvard University · USShadyside Hospital · USUniversity of North Carolina at Chapel Hill · USVanderbilt University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A subset of testicular sex cord-stromal tumors (SCST), which includes neoplasms with mixed histology, cannot be classified into a specific histologic subtype. This study evaluated the clinicopathologic, immunophenotypic and molecular features of 26 SCST not amenable to specific classification by expert uropathologists. Median age at diagnosis was 43 years and median tumor size was 2.4 cm. Follow-up information was available for 18 (69%) patients, with evidence of an aggressive clinical course in 6 patients (4 alive with disease, 2 dead of disease 3 months and 6 months after orchiectomy). Microscopically, SCST not amenable to specific classification demonstrated monophasic epithelioid (9/26, 35%), monophasic spindle cell (5/26, 19%), and biphasic or mixed histology (12/26, 46%). One or more aggressive histopathologic features were seen in 11 cases. DNA sequencing was successful in 22 tumors. Pathogenic CTNNB1 and APC alterations were seen in 7 (33%) and 2 (10%) cases, respectively, with additional variants (e.g., CDKN2A, RB1, TP53, BRCA2) being identified in individual cases. Combined evaluation of morphology, sequencing data and beta-catenin immunohistochemistry resulted in reclassification of 6 (23%) tumors as Sertoli cell tumor, not otherwise specified. This was supported by comparing the methylation profiles of a subset of these tumors and those of typical Sertoli cell tumors. Additionally, a subset of 5 neoplasms (19%) with spindle cell or biphasic histology and SMA expression was characterized by hyperdiploid genomes with recurrent chromosomal gains and absence of driver mutations, possibly representing a distinct tumor type. The SCST that remained not amenable to specific histologic classification (15/26, 58%) were enriched for aggressive histologic features and malignant clinical behavior. In conclusion, this study demonstrated that a subset of testicular SCST that were originally not amenable to specific classification could be reclassified by combined evaluation of morphology, immunohistochemistry and molecular data.

Indexed as

Sex Cord-Gonadal Stromal TumorsTesticular NeoplasmsBiomarkers, TumorHumansImmunohistochemistryMaleBiomarkers, Tumor

Identifiers

PMID36180576
OpenAlexW4298139025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.